August 31, 2015

Our Research

RIFT is a therapeutic antibody company focused on Immuno-Oncology targets outside of the T-cell space.

Specifically, we target clinically implicated immune infiltrating cells in the inflammatory tumor microenvironment, such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs).

By interfering with keystone targets within the inflammatory tumor microenvironment, we aim to disrupt the tumor-permissive conditions and signals that allow the tumor to evade immune surveillance. By crippling that resistance, oncology therapy can then proceed to destroy the tumor efficiently.